Prior RCT showed continuous NSAID slowed XRay progress in SpA. New 2 yr RCT of 109 pts shows when celecoxib added to TNFi Rx (golimumab) in high risk SpA there was no added Xray benefits (by mSASSS). https://t.co/i0KTPAaLFz https://t.co/dB2Q3PHhcK